Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study

Jose R Castillo-Mancilla, Andrew N Phillips, James D Neaton, Jacqueline Neuhaus, Shweta Sharma, Jason V Baker, Simon Collins, Sharon Mannheimer, Sarah Pett, Veronique Touzeau-Römer, Mark N Polizzotto, Jens D Lundgren, Edward M Gardner, INSIGHT START Study Group, Jose R Castillo-Mancilla, Andrew N Phillips, James D Neaton, Jacqueline Neuhaus, Shweta Sharma, Jason V Baker, Simon Collins, Sharon Mannheimer, Sarah Pett, Veronique Touzeau-Römer, Mark N Polizzotto, Jens D Lundgren, Edward M Gardner, INSIGHT START Study Group

Abstract

Introduction: Suboptimal ART adherence, despite HIV viral suppression, has been associated with chronic residual inflammation. Whether this association extends to individuals who initiate ART during early HIV infection remains unknown, which was the objective of this study.

Methods: Plasma levels of interleukin-6 (IL-6), high-sensitivity C-reactive protein, serum amyloid A protein (SAA), IL-27, soluble intercellular adhesion molecule-1, soluble vascular adhesion molecule-1, D-dimer and the CD4+/CD8+ T-cell ratio, were analysed at baseline and eight months after ART initiation in treatment-naïve participants with HIV and CD4+ T-cells >500 cells/mm3 enrolled in the immediate arm of START. Adherence was assessed by seven-day self-report. Multivariable linear regression was utilized to analyse the association between ART adherence and each biomarker at the eight-month visit in participants who achieved virologic suppression (<50 copies/mL).

Results: We evaluated 1627 participants (422 female) who achieved virologic suppression at the eight-month visit in the period between 2009 and 2013. Median (IQR) CD4+ T-cell count before ART was 651 (585, 769) cells/mm3 . Incomplete adherence was reported in 109 (7%) participants at the eight month visit. After adjusting for covariates, plasma IL-6 was 1.12 (95% CI, 1.00 to 1.26; p = 0.047) fold higher in participants reporting incomplete versus 100% adherence. A similar association for SAA was observed in an exploratory analysis (1.29 (95% CI 1.04 to 1.60); p = 0.02). No significant differences in other biomarkers were observed.

Conclusions: Incomplete ART adherence was associated with higher IL-6 levels in individuals who achieved virologic suppression early after ART initiation in START. A potential similar association for SAA requires confirmation. These findings suggest a role for identifying strategies to maximize ART adherence even during virologic suppression. ClinicalTrials.gov number: NCT00867048.

Keywords: START study; adherence; antiretroviral therapy; inflammation; inteleukin-6; serum amyloid A protein.

© 2019 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of the International AIDS Society.

References

    1. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause‐specific mortality among HIV‐infected individuals, by CD4(+) cell count at HAART initiation, compared with HIV‐uninfected individuals. AIDS. 2014;28(2):257–65.
    1. Palella FJ Jr, Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks JT, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43(1):27–34.
    1. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Antiretroviral therapy for the prevention of HIV‐1 transmission. N Engl J Med. 2016;375(9):830–9.
    1. Neuhaus J, Jacobs DR Jr, Baker JV, Calmy A, Duprez D, La Rosa A, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis. 2010;201(12):1788–95.
    1. Tenorio AR, Zheng Y, Bosch RJ, Krishnan S, Rodriguez B, Hunt PW, et al. Soluble markers of inflammation and coagulation but not T‐cell activation predict non‐AIDS‐defining morbid events during suppressive antiretroviral treatment. J Infect Dis. 2014;210(8):1248–59.
    1. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.
    1. Borges AH, Silverberg MJ, Wentworth D, Grulich AE, Fatkenheuer G, Mitsuyasu R, et al. Predicting risk of cancer during HIV infection: the role of inflammatory and coagulation biomarkers. AIDS. 2013;27(9):1433–41.
    1. Saves M, Chene G, Ducimetiere P, Leport C, Le Moal G, Amouyel P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population. Clin Infect Dis. 2003;37(2):292–8.
    1. Bakal D, Coelho L, Luz PM, Clark JL, De Boni R, Cardoso SW, et al., editors. Obesity following antiretroviral therapy (ART) initiation is common and influenced by both traditional and HIV‐/ART‐specific risk factors. Open Forum Infect Dis: 2017;4:S37–8.
    1. Kuniholm MH, O'Brien TR, Prokunina‐Olsson L, Augenbraun M, Plankey M, Karim R, et al. Association of hepatitis C virus infection with CD4/CD8 ratio in HIV‐Positive women. J Acquir Immune Defic Syndr. 2016;72(2):162–70.
    1. Lichtner M, Cicconi P, Vita S, Cozzi‐Lepri A, Galli M, Lo Caputo S, et al. Cytomegalovirus coinfection is associated with an increased risk of severe non‐AIDS‐defining events in a large cohort of HIV‐infected patients. J Infect Dis. 2015;211(2):178–86.
    1. Zeng M, Smith AJ, Wietgrefe SW, Southern PJ, Schacker TW, Reilly CS, et al. Cumulative mechanisms of lymphoid tissue fibrosis and T cell depletion in HIV‐1 and SIV infections. J Clin Invest. 2011;121(3):998–1008.
    1. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, et al. A randomized, controlled trial of raltegravir intensification in antiretroviral‐treated, HIV‐infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011;203(7):960–8.
    1. Hunt PW, Shulman NS, Hayes TL, Dahl V, Somsouk M, Funderburg NT, et al. The immunologic effects of maraviroc intensification in treated HIV‐infected individuals with incomplete CD4+ T‐cell recovery: a randomized trial. Blood. 2013;121(23):4635–46.
    1. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, et al. Valganciclovir reduces T cell activation in HIV‐infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011;203(10):1474–83.
    1. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, et al. Rosuvastatin treatment reduces markers of monocyte activation in HIV‐infected subjects on antiretroviral therapy. Clin Infect Dis. 2014;58(4):588–95.
    1. O'Brien M, Montenont E, Hu L, Nardi MA, Valdes V, Merolla M, et al. Aspirin attenuates platelet activation and immune activation in HIV‐1‐infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr. 2013;63(3):280–8.
    1. Castillo‐Mancilla JR, Brown TT, Erlandson KM, Palella FJ Jr, Gardner EM, Macatangay BJ, et al. Suboptimal adherence to combination antiretroviral therapy is associated with higher levels of inflammation despite HIV suppression. Clin Infect Dis. 2016;63(12):1661–7.
    1. Castillo‐Mancilla J, Morrow M, Boum Y, Byakwaga H, Haberer J, Martin J, et al. Higher ART adherence is associated with lower systemic inflammation in treatment‐naïve Ugandans who achieve virologic suppression. J Acquir Immune Defic Syndr. 2018.
    1. Castillo‐Mancilla J, Phillips A, Neaton JD, Neuhaus J, Collins S, Mannheimer S, et al. Association of suboptimal antiretroviral therapy (ART) adherence with inflammation in virologically‐suppressed, HIV‐infected individuals: a sub‐analysis of the strategies for management of antiretroviral therapy (SMART) study. Open Forum Infect Dis. 2018;5(1):ofx275.
    1. Group ISS . Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.
    1. O'connor J, Gardner E, Esser S, Mannheimer S, Lifson A, Telzak E, et al. A simple self‐reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy. HIV Med. 2016;17(2):124–32.
    1. Mannheimer S, Friedland G, Matts J, Child C, Chesney M; AIDS TBCPfCRo . The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus – infected persons in clinical trials. Clin Infect Dis. 2002;34(8):1115–21.
    1. Baker JV, Sharma S, Grund B, Rupert A, Metcalf JA, Schechter M, et al., editors. Systemic inflammation, coagulation, and clinical risk in the START trial. Open Forum Infect Dis. 2017;4(4):ofx262.
    1. Borges AH, O'Connor JL, Phillips AN, Ronsholt FF, Pett S, Vjecha MJ, et al. Factors associated with plasma IL‐6 levels during HIV infection. J Infect Dis. 2015;212(4):585–95.
    1. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5(10):e203.
    1. Kingsley L, Jacobson LP. Determinants of heterogeneous adherence to HIV‐antiretroviral therapies in the Multicenter AIDS Cohort Study. J Acqui Immune Defic Syndr. 2001;26:8292.
    1. O'Cleirigh C, Valentine SE, Pinkston M, Herman D, Bedoya CA, Gordon JR, et al. The unique challenges facing HIV‐positive patients who smoke cigarettes: HIV viremia, art adherence, engagement in HIV care, and concurrent substance use. AIDS Behav. 2015;19(1):178–85.
    1. Hudelson C, Cluver L. Factors associated with adherence to antiretroviral therapy among adolescents living with HIV/AIDS in low‐ and middle‐income countries: a systematic review. AIDS Care. 2015;27(7):805–16.
    1. O'Brien PC. Procedures for comparing samples with multiple endpoints. Biometrics. 1984;40:1079–87.
    1. Dallow NS, Leonov SL, Roger JH. Practical usage of O'Brien's OLS and GLS statistics in clinical trials. Pharm Stat. 2008;7:53‐68.
    1. Hsu DC, Ma YF, Hur S, Li D, Rupert A, Scherzer R, et al. Plasma IL‐6 levels are independently associated with atherosclerosis and mortality in HIV‐infected individuals on suppressive ART. AIDS. 2016;30(13):2065–74.
    1. Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi‐Lepri A, et al. Relevance of interleukin‐6 and D‐dimer for serious non‐AIDS morbidity and death among HIV‐positive adults on suppressive antiretroviral therapy. PLoS ONE. 2016;11(5):e0155100.
    1. Hunt PW, Lee SA, Siedner MJ. Immunologic biomarkers, morbidity, and mortality in treated HIV infection. J Infect Dis. 2016;214 Suppl_2:S44–50.
    1. Gandhi M, Gandhi RT, Stefanescu A, Bosch RJ, Cyktor JC, Horng H, et al. Cumulative antiretroviral exposure measured in hair is not associated with measures of HIV persistence or inflammation among individuals on suppressive ART. J Infect Dis. 2018;218:234–8.
    1. Borges AH, O'Connor JL, Phillips AN, Neaton JD, Grund B, Neuhaus J, et al. Interleukin 6 is a stronger predictor of clinical events than high‐sensitivity C‐reactive protein or D‐dimer during HIV infection. J Infect Dis. 2016;214(3):408–16.
    1. Serrano‐Villar S, Sainz T, Lee SA, Hunt PW, Sinclair E, Shacklett BL, et al. HIV‐infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non‐AIDS morbidity and mortality. PLoS Pathog. 2014;10(5):e1004078.
    1. Yamada T. Serum amyloid A (SAA): a concise review of biology, assay methods and clinical usefulness. Clinical Chem Lab Med. 1999;37(4):381–8.
    1. Steel DM, Whitehead AS. The major acute phase reactants: C‐reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994;15(2):81–8.
    1. Targońska‐Stępniak B, Majdan M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm. 2014;2014:793628.
    1. Johnson BD, Kip KE, Marroquin OC, Ridker PM, Kelsey SF, Shaw LJ, et al. Serum amyloid A as a predictor of coronary artery disease and cardiovascular outcome in women: the National Heart, Lung, and Blood Institute‐Sponsored Women's Ischemia Syndrome Evaluation (WISE). Circulation. 2004;109(6):726–32.
    1. Yang R‐Z, Lee M‐J, Hu H, Pollin TI, Ryan AS, Nicklas BJ, et al. Acute‐phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med. 2006;3(6):e287.
    1. Wirunsawanya K, Belyea L, Shikuma C, Watanabe RM, Kohorn L, Shiramizu B, et al. Plasminogen activator inhibitor‐1 predicts negative alterations in whole‐body insulin sensitivity in chronic HIV infection. AIDS Res Hum Retroviruses. 2017;33(7):723–7.
    1. O'brien KD, Brehm BJ, Seeley RJ, Bean J, Wener MH, Daniels S, et al. Diet‐induced weight loss is associated with decreases in plasma serum amyloid a and C‐reactive protein independent of dietary macronutrient composition in obese subjects. J Clin Endocrinol Metab. 2005;90(4):2244–9.
    1. Mohanty P, Aljada A, Ghanim H, Hofmeyer D, Tripathy D, Syed T, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. J Clin Endocrinol Metab. 2004;89(6):2728–35.
    1. Kramer HB, Lavender KJ, Qin L, Stacey AR, Liu MK, Di Gleria K, et al. Elevation of intact and proteolytic fragments of acute phase proteins constitutes the earliest systemic antiviral response in HIV‐1 infection. PLoS Pathog. 2010;6(5):e1000893.
    1. Arenas‐Pinto A, Milinkovic A, Peppa D, McKendry A, Maini M, Gilson R. Systemic inflammation and residual viraemia in HIV‐positive adults on protease inhibitor monotherapy: a cross‐sectional study. BMC Infect Dis. 2015;15(1):138.
    1. Rodger AJ, Fox Z, Lundgren JD, Kuller LH, Boesecke C, Gey D, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis. 2009;200(6):973–83.
    1. de Truchis P, Assoumou L, Landman R. No increase in HIV‐1 reservoir and inflammation markers in four days a week short‐cycles maintenance therapy: the ANRS 162‐4D trial. Poster Presented at: IAS 2017: 9th IAS Conference on HIV Pathogenesis Treatment and Prevention; July 23–26, Paris, France; 2017.
    1. Breather T. Weekends‐off efavirenz‐based antiretroviral therapy in HIV‐infected children, adolescents, and young adults (BREATHER): a randomised, open‐label, non‐inferiority, phase 2/3 trial. Lancet HIV. 2016;3(9):e421.
    1. Rojas J, Blanco JL, Sanchez‐Palomino S, Marcos MA, Guardo AC, Gonzalez‐Cordon A, et al. A maintenance three‐day‐per‐week schedule with the single tablet regimen efavirenz/emtricitabine/tenofovir disoproxil fumarate is effective and decreases sub‐clinical toxicity: the A‐TRI‐WEEK pilot trial. AIDS. 2018;32:1633–1641.
    1. Viswanathan S, Detels R, Mehta SH, Macatangay BJ, Kirk GD, Jacobson LP. Level of adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy (HAART). AIDS Behav. 2015;19(4):601–11.
    1. Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, et al. Antiretroviral therapy adherence and viral suppression in HIV‐infected drug users: comparison of self‐report and electronic monitoring. Clin Infect Dis. 2001;33(8):1417–23.
    1. Group CDPR . Influence of adherence to treatment and response of cholesterol on mortality in the Coronary Drug Project. N Engl J Med. 1980;303(18):1038–41.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren